Best HealthTech Companies to Work for in the UK
Amidst the COVID-19 pandemic, there has been a massive demand for HealthTech companies to provide medical therapies and innovations to improve outcomes and healthcare delivery across the UK. The pandemic has also contributed to an already growing HealthTech sector, and investment reached record highs in 2021.
The US leads globally with $31.9 billion in VC investment, while the UK came in third with $3.8 billion in 2021. The UK HealthTech investment has risen from just $420 million in 2016, which is an increase of nine times, while US investment has increased by 3.4 times.
Not only are HealthTech companies a good investment, but they have created massive job openings. Here is a list of the most prodigious UK HealthTech companies that deserve your attention in 2022.
FundamentalVR is a London-based deep IP company working at the intersection of immersive technology (XR), haptics, and machine learning to bring simulation into the hands of medical professionals worldwide by using the latest software combined with low-cost, readily available technology.
Through their Fundamental Surgery programme, they aim to allow orthopaedical surgeons to rehearse, practice, and test themselves within a safe, controllable space as close to real-life. Key surgical objectives and actions are given specific measurement requirements that are instantly assessed as users interact. Feedback is delivered using audible, visual, and haptic mechanisms. All data on knowledge and skills development is securely held for later review.
Fundamental Surgery is accredited by leading institutions, including AAOS and the Royal College of Surgeons and practising surgeons in the USA are required to maintain their license to practice and as part of their requirements to maintain and develop their knowledge and skills, surgeons must undertake Continual Medical Education (CME) activities.
Artios Pharma is a Cambridge-based DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 in patients with advanced or metastatic solid tumours.
In addition, Artios is building a pipeline of next-generation DDR programmes, including a unique partnership with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK (CRUK), with leading DNA repair researchers worldwide.
The company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, and Arix Bioscience PLC.
CMR Surgical is another Cambridge-based medical devices company dedicated to transforming surgery with Versius®, a next-generation surgical robot. Versius has a small, lightweight and modular design that can be moved effortlessly between departments to help hospitals maximise its utilisation. The small-scale design, enabled by unique v-wrist technology, is suitable for virtually any operating room.
CMR works with surgeons, surgical teams, and hospital partners to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. The benefits of minimal access surgery for patients are well proven and include reduced pain and surgical site infections and reduced likelihood of other surgical complications.
Medronic Digital Surgery
Medronic Digital Surgery’s programme Touch Surgery helps surgeons and health systems deliver consistent and high-quality surgery through AI, data, and visualisation. The Touch Surgery app, the world’s first academically validated mobile-based cognitive simulator, allows surgeons, trainees, and patients to train, prepare and better understand surgical steps. With more than 5 million downloads globally, the award-winning platform is free to download on iOS and Android.
Wren Technologies Ltd
Wren Technologies Ltd is a spin-off company from the University of Cambridge and Lund University (Sweden), focused on drug discovery and development for protein misfolding diseases. Wren is advancing an entirely novel approach to address this class of diseases, based on more than a decade of research from its scientific founders focused on the chemical kinetics of the protein misfolding process.
Wren’s predictive, quantitative platform is built on concepts from the physical sciences and is a fundamental shift from traditional biology’s descriptive, qualitative methods, which have failed to successfully address these complex systems. Wren is using its unique approach to develop a broad pipeline of small molecule and antibody therapeutics and diagnostics, spanning neurology, ophthalmology, and metabolic diseases.
Camallergy is a biopharmaceutical company dedicated to providing innovative, patient-centric treatments to address the millions of people worldwide who suffer from food allergies. Camallergy’s lead product, CA002, is novel oral immunotherapy for the treatment of peanut allergy designed to offer “bite-proof” protection to patients within 14 weeks of therapy.
The company’s unique intellectual property and treatment regimen is based on the clinical work initiated at Cambridge University Hospitals NHS Foundation Trust in Cambridge, U.K., by the company’s scientific co-founders, Dr Andrew Clark and Dr Pamela Ewan. Camallergy has its headquarters in Cambridge, UK, with essential functions and members of its leadership team located in the United States.